Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 7:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 29,129 matching trials from the live ClinicalTrials.gov search.
Conditions
Breast Cancer Related Lymphedema, Covid19
Interventions
Survey
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 2 Interventional Results available

Dose Ranging Study of OTO-201 in AOMT

NCT02719158
Conditions
Acute Otitis Media, AOMT
Interventions
6 mg ciprofloxacin, 12 mg ciprofloxacin, Sham
Drug · Other
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
San Diego, California
Conditions
Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
Interventions
tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 10 more
Conditions
Recurrent Platinum Resistant Ovarian Cancer
Interventions
VB-111 + Paclitaxel, Placebo + Paclitaxel
Drug
Lead sponsor
Vascular Biogenics Ltd. operating as VBL Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
64
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 56 more
Completed Phase 1Phase 2 Interventional Results available

Calcineurin Inhibitor Sparing After Kidney Transplantation

NCT01062555
Conditions
CNI Side Effects
Interventions
Cyclosporine & Cellcept, Prograf & Cellcept, Low Dose CNI (Cyclosporine or FK) and Cellcept, Rapamune and Cellcept
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Rheumatoid Arthritis
Interventions
89Zr-DFO-CZP
Drug
Lead sponsor
Robert Flavell, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
1
States / cities
San Francisco, California
Conditions
Obesity, Overweight
Interventions
AC2307, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
18
States / cities
Birmingham, Alabama • Chandler, Arizona • Santa Rosa, California + 15 more
Conditions
Renal Cell Carcinoma
Interventions
everolimus and bevacizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Conditions
Healthy Volunteers
Interventions
INS1007, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 50 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Glendale, California
Conditions
Carcinoma, Islet Cell, Carcinoma, Pancreas
Interventions
sunitinib malate, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
14
States / cities
Aurora, Colorado • Iowa City, Iowa • Worcester, Massachusetts + 6 more
Conditions
Tumor, Solid
Interventions
Indocyanine Green
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Leukemia
Interventions
Autologous CD5.CAR/28zeta CAR T cells, Allogeneic CD5.CAR/28zeta CAR T cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 75 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2040
U.S. locations
2
States / cities
Houston, Texas
Conditions
Solid Tumors
Interventions
nesvacumab (REGN910/ SAR307746), aflibercept (ziv-aflibercept)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Indianapolis, Indiana • New York, New York • Oklahoma City, Oklahoma + 2 more
Conditions
Healthy Volunteer
Interventions
CC-90009, [14C]
Drug · Radiation
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Beta-Thalassemia
Interventions
ACE-536
Drug
Lead sponsor
Celgene
Industry
Eligibility
6 Years to 17 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2035
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Conditions
Unresectable Melanoma
Interventions
Nivolumab, Duvelisib
Drug
Lead sponsor
John Kirkwood
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate, Histamine base
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
28
States / cities
Oxford, Alabama • Stockbridge, Georgia • Normal, Illinois + 22 more
Conditions
Glioblastoma Multiforme
Interventions
Temozolomide, radiation therapy, Ascorbic Acid
Drug · Radiation
Lead sponsor
Bryan Allen
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Rectal Adenocarcinoma
Interventions
Radiation, Bavituximab, Capecitabine
Radiation · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Etelcalcetide, Standard of Care
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
0 Years to 18 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Kansas City, Missouri + 7 more
Conditions
Chronic Granulomatous Disease, Granulomatous Disease, Chronic
Interventions
PM359
Biological
Lead sponsor
Prime Medicine, Inc.
Industry
Eligibility
6 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
3
States / cities
Los Angeles, California • Bethesda, Maryland • Nashville, Tennessee
Conditions
Non-Small Cell Lung Cancer
Interventions
Durvalumab, Proton beam therapy RT
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Healthy Volunteers
Interventions
TEV-56286, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miramar, Florida
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Aleniglipron Renal Impairment Study

NCT07946068
Conditions
Renal Impairment, Severe Renal Impairment
Interventions
Aleniglipron
Drug
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Orlando, Florida